Search Result "acquired gefitinib-resistance"
An Anti-EGFR/anti- HER2 Bispecific Antibody with Enhanced Antitumor Activity Against Acquired Gefitinib-Resistant NSCLC Cells
Journal: Protein & Peptide Letters
Volume: 28 Issue: 11 Year: 2021 Page: 1290-1297
Author(s): Yan Si,Xinxin Pei,Xiangfang Wang,Qianqian Han,Changzhi Xu,Buchang Zhang
Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway
Journal: Current Cancer Drug Targets
Volume: 17 Issue: 4 Year: 2017 Page: 376-385
Author(s): Ruzhen Zheng,Hao Jiang,Jinhui Li,Xinge Liu,Hongwei Xu
Pulmonary Adenocarcinoma Patient with Complex Mutations on EGFRBenefits from Furmonertinib after Acquiring Gefitinib Resistance: A CaseReport
Journal: Recent Patents on Anti-Cancer Drug Discovery
Volume: 19 Issue: 2 Year: 2024 Page: 247-252
Author(s):
Combined Treatment with JFKD and Gefitinib Overcomes Drug Resistance in Non-Small Cell Lung Cancer
Journal: Current Pharmaceutical Biotechnology
Volume: 22 Issue: 3 Year: 2021 Page: 389-399
Author(s): Xiaoming Huang,Jingchun Sun,Jianli Sun
An Integrative Analysis of the Putative Gefitinib-resistance Related Genes in a Lung Cancer Cell Line Model System
Journal: Current Cancer Drug Targets
Volume: 15 Issue: 5 Year: 2015 Page: 423-434
Author(s): Xiaohong Han,Manjiao Liu,Shuai Wang,Guanting Lv,Li Ma,Changqing Zeng,Yuankai Shi
Combined Cancer Therapy: Strategies to Overcome Acquired Aromatase Inhibitor Resistance
Journal: Current Pharmaceutical Design
Volume: 20 Issue: 42 Year: 2014 Page: 6575-6583
Author(s): Susan B. Kesmodel,Gauri J. Sabnis,Saranya Chumsri,Angela M.H. Brodie
Structural Basis for Drug Resistance Mechanisms Against EGFR
Journal: Current Topics in Medicinal Chemistry
Volume: 17 Issue: 22 Year: 2017 Page: 2509-2521
Author(s): Sukriti Goyal,Salma Jamal,Asheesh Shanker,Abhinav Grover
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer
Journal: Current Pharmaceutical Design
Volume: 19 Issue: 5 Year: 2013 Page: 818-832
Author(s): Elena Galvani,Roberta Alfieri,Elisa Giovannetti,Andrea Cavazzoni,Silvia La Monica,Maricla Galetti,Claudia Fumarola,Mara Bonelli,Marco Mor,Marcello Tiseo,Godefridus J. Peters,Pier Giorgio Petronini,Andrea Ardizzoni
Irreversible EGFR Inhibitors in the Treatment of Advanced NSCLC
Journal: Current Pharmaceutical Design
Volume: 20 Issue: 24 Year: 2014 Page: 3894-3900
Author(s): Paolo Maione,Antonio Rossi,Marianna Bareschino,Paola Claudia Sacco,Clorinda Schettino,Francesca Casaluce,Assunta Sgambato,Cesare Gridelli
Signaling Pathways Modulating Dependence of Lung Cancer on Mutant Epidermal Growth Factor Receptor and Mechanisms of Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors
Journal: Current Pharmaceutical Design
Volume: 20 Issue: 24 Year: 2014 Page: 3883-3893
Author(s): Luciano Wannesson,Santiago Viteri,Carlota Costa,Niki Karachaliou,Miguel Angel Molina-Vila,Rafael Rosell